MISSISSAUGA, ON, Nov. 12, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, is delighted to announce the appointment of Danny Brannagan as Chief Financial Officer.
Mr. Brannagan has been managing Covalon's finance team since joining the Company in November 2014. Mr. Brannagan is a Chartered Accountant and Certified Professional Accountant and holds a Bachelors of Commerce degree from Queen's University. Prior to joining Covalon, Danny spent several years with PriceWaterhouse Coopers LLP in the tax and assurance groups advising public and private companies on taxation and financial accounting matters. Prior to joining PriceWaterhouse Coopers LLP Mr. Brannagan was a professional football player with the Toronto Argonauts where he became the first Canadian-born quarterback to play for the Argonauts since 1969.
"Covalon is fortunate to have Danny lead our finance team and we are excited to appoint Danny as our chief financial officer," said Brian Pedlar, Covalon's CEO and former Interim CFO. "Since joining Covalon, Danny has taken over the leadership of our finance group and has been successful in leading the Company financially through significant growth and change. Danny has played an instrumental role in financial reporting, international business expansion, and contact negotiations over the past year as Covalon has expanded its markets internationally and launched new products. Our board of directors unanimously support the appointment of Danny as the Company's chief financial officer."
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.
For further information: To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: [email protected], Phone: 905.568.8400 x 233, Toll free: 1.877.711.6055, Web site: www.covalon.com, Twitter: @covalon